Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study

INTRODUCTION: Nocturnal hypertension is clinically important for patients with type 2 diabetes (T2D), considering its strong correlation with cardiovascular events. We aim to test the hypothesis that the sodium-glucose cotransporter 2 inhibitor, luseogliflozin, ameliorates nocturnal hypertension mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kameda, Reina, Nomoto, Hiroshi, Cho, Kyu Yong, Kawata, Shinichiro, Omori, Kazuno, Takeuchi, Jun, Nagai, So, Kurihara, Yoshio, Aoki, Shin, Nakamura, Akinobu, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044823/
https://www.ncbi.nlm.nih.gov/pubmed/32034028
http://dx.doi.org/10.1136/bmjopen-2019-034883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044823/
https://www.ncbi.nlm.nih.gov/pubmed/32034028
http://dx.doi.org/10.1136/bmjopen-2019-034883

Ejemplares similares